UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

18 BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Read More Share:

Oct

18 Evolving Expectations for Dermatological Conditions

Read More Share:

Oct

17 UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Read More Share:

Oct

17 Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio

Read More Share:

Oct

13 UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More Share:

Oct

13 Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Read More Share:

Oct

12 Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Read More Share:

Oct

04 UCB presents late-breaking posters at Child Neurology Society Meeting

Read More Share:

Oct

02 “Disease modification” in epilepsies: key questions answered

Read More Share:

Sep

28 Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

Read More Share:

Categories

Archives

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

Evolving Expectations for Dermatological Conditions

Oct

17

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Oct

17

Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Oct

12

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Oct

02

“Disease modification” in epilepsies: key questions answered

Sep

28

Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

Choose Country

UCB in the U.S.

Patients

Innovation

Sustainability

Newsroom

Contact

Categories

Archives

Oct

18

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Oct

18

Evolving Expectations for Dermatological Conditions

Oct

17

UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Oct

17

Steadfast Towards Our Ambition to Create a UCB Rare Disease Portfolio

Oct

13

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Oct

13

Going Beyond the Medicine: How UCB Is Addressing the Needs of People Living with Hidradenitis Suppurativa

Oct

12

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Oct

04

UCB presents late-breaking posters at Child Neurology Society Meeting

Oct

02

“Disease modification” in epilepsies: key questions answered

Sep

28

Employee Spotlight: Jessie Kim's Journey as a Global Regulatory Fellow

Choose Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Sustainability

Newsroom

Contact